Education
About Us
Working with TipRanks
Follow Us
ImmunityBio (IBRX)
NASDAQ:IBRX
IBRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.83 - $7.48
Previous CloseN/A
Volume1.20M
Average Volume (3M)10.85M
Market Cap
$2.36B
Enterprise Value$3.03B
Total Cash (Recent Filing)$153.66M
Total Debt (Recent Filing)$535.32M
Price to Earnings (P/E)―
Beta2.09
Next Earnings
Nov 07, 2025EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding945,254,700
10 Day Avg. Volume12,132,119
30 Day Avg. Volume10,846,627
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.28
Enterprise Value/Revenue53.62
Enterprise Value/Gross Profit53.80
Enterprise Value/Ebitda-16.63
Forecast
1Y Price Target
$7.00Price Target Upside175.59% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
International ExpansionThe U.K. approval marks a key international milestone for Anktiva, representing a significant step in ImmunityBio's global strategy and affirming the strength of Anktiva’s underlying data.
Market AdoptionUnit volumes have increased 246%, reinforcing physician confidence in ANKTIVA’s clinical durability, favorable safety, and seamless integration into urologic workflows.
Sales GrowthANKTIVA's sales reached $26.4M, reflecting 60% quarter-over-quarter growth, driven by increasing adoption in U.S. urology practices.
Bears Say
Regulatory ChallengesThe FDA raised concerns about the single-arm design of the QUILT-3.032 Cohort B study during the Type A meeting regarding ANKTIVA’s supplemental BLA.
Regulatory SetbacksIn May 2025, ImmunityBio announced it received a surprising Refusal to File (RTF) letter from the FDA regarding its supplemental BLA for ANKTIVA plus BCG in BCG-unresponsive NMIBC patients with papillary-only disease.
ImmunityBio News
IBRX FAQ
What was ImmunityBio’s price range in the past 12 months?
ImmunityBio lowest stock price was $1.83 and its highest was $7.48 in the past 12 months.
What is ImmunityBio’s market cap?
ImmunityBio’s market cap is $2.36B.
When is ImmunityBio’s upcoming earnings report date?
ImmunityBio’s upcoming earnings report date is Nov 07, 2025 which is in 40 days.
How were ImmunityBio’s earnings last quarter?
ImmunityBio released its earnings results on Aug 05, 2025. The company reported -$0.1 earnings per share for the quarter, beating the consensus estimate of -$0.108 by $0.008.
Is ImmunityBio overvalued?
According to Wall Street analysts ImmunityBio’s price is currently Undervalued.
Does ImmunityBio pay dividends?
ImmunityBio does not currently pay dividends.
What is ImmunityBio’s EPS estimate?
ImmunityBio’s EPS estimate is -0.11.
How many shares outstanding does ImmunityBio have?
ImmunityBio has 945,254,700 shares outstanding.
What happened to ImmunityBio’s price movement after its last earnings report?
ImmunityBio reported an EPS of -$0.1 in its last earnings report, beating expectations of -$0.108. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of ImmunityBio?
Currently, no hedge funds are holding shares in IBRX
ImmunityBio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.00 (175.59% Upside)
$7.00 (175.59% Upside)
Blogger Sentiment
Bullish
IBRX Sentiment 75%
Sector Average 73%
Sector Average 73%
Hedge Fund Trend
Increased
By 774.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.0%
Last 30 Days ▲ 17.4%
Last 30 Days ▲ 17.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.89%
12-Months-Change
Fundamentals
Return on Equity
78.99%
Trailing 12-Months
Asset Growth
-9.51%
Trailing 12-Months
Company Description
ImmunityBio
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.
IBRX Stock 12 Month Forecast
Average Price Target
$7.00
▲(175.59% Upside)
Technical Analysis
Catalyst Pharma
―
Immunovant
―
Arcutis Biotherapeutics
―
Beam Therapeutics
―
Immunocore Holdings
―
Ownership Overview
69.21% Insiders
2.83% Mutual Funds
2.57% Other Institutional Investors
21.49% Public Companies and Individual Investors